Taft Acts as Legal Counsel to Advanced NanoTherapies in Strategic Investment
Taft is pleased to have acted as legal counsel to Advanced NanoTherapies (ANT) in a $4 million Series A extension from a prominent undisclosed strategic medical device company. The investment will be used for ANT’s clinical programs and to accelerate the path toward U.S. IDE approval for the SirPlux Duo Drug-Coated Balloon.
ANT is a highly specialized medical device company developing a nanoparticle technology-based platform for drug delivery. Read the release here.
Taft’s legal team included Brandi Weekley and Abe Wehbi.
In This Article
You May Also Like
Cook, Fry, Fulmer, Hayden, and Kline to Speak at 2026 Ohio Tax Conference Meister Appointed Co-Chair of ABA Probate & Fiduciary Litigation Committee